{"classes":[{"categories":[{"measurements":[{"comment":"Median and 95% confidence interval were not reached due to an insufficient events being observed.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"95% confidence interval was not reached due to an insufficient events being observed.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"4.3"},{"comment":"Upper limit of 95% confidence interval was not reached due to an insufficient events being observed.","groupId":"OG002","lowerLimit":"6.3","upperLimit":"NA","value":"6.4"},{"comment":"Median and upper limit of 95% confidence interval were not reached due to an insufficient events being observed.","groupId":"OG003","lowerLimit":"6.7","upperLimit":"NA","value":"NA"},{"comment":"Upper limit of 95% confidence interval was not reached due to an insufficient events being observed.","groupId":"OG004","lowerLimit":"3.1","upperLimit":"NA","value":"14.5"},{"groupId":"OG005","lowerLimit":"2.2","upperLimit":"12.1","value":"7.6"},{"comment":"95% confidence interval was not reached due to an insufficient events being observed.","groupId":"OG006","lowerLimit":"NA","upperLimit":"NA","value":"44.5"},{"comment":"Upper limit of 95% confidence interval was not reached due to an insufficient events being observed.","groupId":"OG007","lowerLimit":"6.7","upperLimit":"NA","value":"6.7"},{"comment":"95% confidence interval was not reached due to an insufficient events being observed.","groupId":"OG008","lowerLimit":"NA","upperLimit":"NA","value":"14.3"},{"comment":"Upper limit of 95% confidence interval was not reached due to an insufficient events being observed.","groupId":"OG009","lowerLimit":"4.3","upperLimit":"NA","value":"7.7"},{"comment":"Upper limit of 95% confidence interval was not reached due to an insufficient events being observed.","groupId":"OG010","lowerLimit":"0.4","upperLimit":"NA","value":"21.7"},{"groupId":"OG011","lowerLimit":"4.1","upperLimit":"25.9","value":"16.5"},{"groupId":"OG012","lowerLimit":"3.6","upperLimit":"19.1","value":"8.6"},{"groupId":"OG013","lowerLimit":"4.0","upperLimit":"14.9","value":"9.2"},{"groupId":"OG014","lowerLimit":"5.7","upperLimit":"24.3","value":"17.1"},{"groupId":"OG015","lowerLimit":"5.2","upperLimit":"11.6","value":"7.0"},{"groupId":"OG016","lowerLimit":"6.5","upperLimit":"12.4","value":"8.4"},{"groupId":"OG017","lowerLimit":"8.0","upperLimit":"15.5","value":"11.3"},{"groupId":"OG018","lowerLimit":"5.8","upperLimit":"14.1","value":"8.7"},{"groupId":"OG019","lowerLimit":"4.1","upperLimit":"12.9","value":"8.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"6"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"22"},{"groupId":"OG012","value":"16"},{"groupId":"OG013","value":"25"},{"groupId":"OG014","value":"25"},{"groupId":"OG015","value":"44"},{"groupId":"OG016","value":"25"},{"groupId":"OG017","value":"55"},{"groupId":"OG018","value":"21"},{"groupId":"OG019","value":"26"}],"units":"Participants"}],"description":"Overall survival was defined as the number of months from date of first study drug administration to death. The OS was estimated using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.3 mg/kg 1Q3W until the end of treatment.","id":"OG000","title":"Dose-escalation Part: Enapotamab Vedotin 0.3 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.6 mg/kg 1Q3W until the end of treatment.","id":"OG001","title":"Dose-escalation Part: Enapotamab Vedotin 0.6 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.0 mg/kg 1Q3W until the end of treatment.","id":"OG002","title":"Dose-escalation Part: Enapotamab Vedotin 1.0 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.5 mg/kg 1Q3W until the end of treatment.","id":"OG003","title":"Dose-escalation Part: Enapotamab Vedotin 1.5 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 2.0 mg/kg 1Q3W until the end of treatment.","id":"OG004","title":"Dose-escalation Part: Enapotamab Vedotin 2.0 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG005","title":"Dose-escalation Part: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 2.4 mg/kg 1Q3W until the end of treatment.","id":"OG006","title":"Dose-escalation Part: Enapotamab Vedotin 2.4 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.6 mg/kg 3Q4W until the end of treatment.","id":"OG007","title":"Dose-escalation Part: Enapotamab Vedotin 0.6 mg/kg 3Q4W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.8 mg/kg 3Q4W until the end of treatment.","id":"OG008","title":"Dose-escalation Part: Enapotamab Vedotin 0.8 mg/kg 3Q4W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.0 mg/kg 3Q4W until the end of treatment.","id":"OG009","title":"Dose-escalation Part: Enapotamab Vedotin 1.0 mg/kg 3Q4W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.2 mg/kg 3Q4W until the end of treatment.","id":"OG010","title":"Dose-escalation Part: Enapotamab Vedotin 1.2 mg/kg 3Q4W"},{"description":"Participants with advanced and/or metastatic NSCLC with classical sensitizing EGFR mutations and/or EGFR mutations targeted by third-generation tyrosine kinase inhibitors) received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG011","title":"Expansion Part Cohort 1: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic melanoma with BRAF V600 mutation received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG012","title":"Expansion Part Cohort 3: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic melanoma with BRAF V600 wild type received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG013","title":"Expansion Part Cohort 4: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic sarcoma received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.st.","id":"OG014","title":"Expansion Part Cohort 5: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic solid tumors (excluding NSCLC, melanoma, sarcoma, and ovarian cancer unless having a known AXL gene amplification) received IV infusion of enapotamab vedotin 1.0 mg/kg 3Q4W until the end of treatment.","id":"OG015","title":"Expansion Part Cohort 6: Enapotamab Vedotin 1.0 mg/kg 3Q4W"},{"description":"Participants with advanced and/or metastatic platinum-resistant ovarian cancer received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG016","title":"Expansion Part Cohort 7: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic NSCLC without activating EGFR mutations or ALK rearrangements received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG017","title":"Expansion Part Cohort 2: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic NSCLC without activating EGFR mutations or ALK rearrangements received IV infusion of enapotamab vedotin 1.8 mg/kg 1Q3W until the end of treatment.","id":"OG018","title":"Expansion Part Cohort 2: Enapotamab Vedotin 1.8 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic NSCLC without activating EGFR mutations or ALK rearrangements received IV infusion of enapotamab vedotin 1.0 mg/kg 3Q4W until the end of treatment.","id":"OG019","title":"Expansion Part Cohort 8: Enapotamab Vedotin 1.0 mg/kg 3Q4W"}],"paramType":"MEDIAN","populationDescription":"The full analysis set included all participants who received at least 1 dose of enapotamab vedotin. Participants were classified according to first dose received.","reportingStatus":"POSTED","timeFrame":"Day 1 through 44.5 months (maximum observed duration)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}